Currently, the most common treatment used in metastatic colorectal cancer (mCRC) is represented by chemotherapy regimens constituting oxaliplatin, 5-fluorouracil, and/or irinotecan in combination with targeted agents including bevacizumab or aflibercept (antiangiogenic agents) and, according to the RAS/BRAF status, cetuximab or panitumumab (anti-epidermal growth factor receptor (EGFR) drugs) [4]. Here, EGFR is linked to metastatic colorectal cancer.